PATENT CLAIM ANALYSIS

Application Number: 16431422
Application Type: Utility
Filing Date: 2019-06
Publication Date: 2019-09
Patent Classification: ["514", "318000"]

Abstract:
The present technology is directed to compositions comprising d-threo-methylphenidate conjugates and unconjugated methylphenidate. The present technology also relates to compositions and oral formulations comprising d-threo-methylphenidate conjugated to nicotinoyl-L-serine, and/or a pharmaceutically acceptable salt thereof, and unconjugated methylphenidate and/or a pharmaceutically acceptable salt thereof. The present technology additionally relates to a pharmaceutical kit containing the composition comprising d-threo-methylphenidate conjugated to nicotinoyl-L-serine, and/or a pharmaceutically acceptable salt thereof, and unconjugated methylphenidate and/or a pharmaceutically acceptable salt thereof.

Claim (Index 118):
The composition of  claim 117 , wherein the composition provides a dose amount that is the molar equivalent to a dose from about 1 mg to about 400 mg d-methylphenidate hydrochloride per dose.

Metadata:
- Claim Count in Document: 311.0
- Percentile: 100.0
- Lexical Diversity: 2.48485
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16431275', '14234440', '15249088', '14727498', '14299421']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8220144314544456
- 35 USC 102 Novelty (BERT): 0.6127156566873048
- Combined Prediction Score: 0.8010845539777316
- Mean Citation Score: 461.262296
- Max Citation Score: 685.40857
- Similarity Product: 465.142449980156

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test